维奈克拉及联合用药在急性髓细胞白血病治疗中的研究进展  

Research Progress of Venetoclax and Drug Combination in Treatment of Acute Myeloid Leukemia

作　　者：陈孟斯 CHEN Mengsi(Chengdu University of Traditional Chinese Medicine,Chengdu,Sichuan 610032)

机构地区：[1]成都中医药大学,四川成都610032

出　　处：《智慧健康》2024年第34期8-11,共4页Smart Healthcare

摘　　要：在过去几十年里,急性髓细胞白血病(AML)患者标准治疗方案并没有作出明显的改变,老年性、复发性、难治性AML长期生存率也没有得到显著改善,该病的发病率随着年龄增长而增大,且患者的年龄越大,其预后效果就相对越差。B细胞淋巴癌2基因(Bcl-2)为线粒体凋亡过程中的重要调节剂,维奈克拉(Ven)作为首个获准上市的Bcl-2抑制剂,在AML的治疗中显示出较高的安全性,并对肿瘤细胞的程序性死亡过程起到至关重要的作用。但和其他联合用药方案相比,单独用药的效果相对有限,且容易发生耐药,所以联合用药当前已经变成一种治疗的新趋势。近年来诸多研究发现,以Ven作为基础的诱导化疗和传统的化疗相比其疗效更明显,安全性更高,且Ven的出现及应用大大改变了AML治疗的格局,特别是对于复杂性、难治性AML以及不适合采用强化化疗的老年AML治疗效果更为明显。对此,本文主要以Bcl-2抑制剂Ven联合化疗药物治疗AML的研究进展加以综述。During the past decades,there was no significant changes of standard treatment scheme for patients with acute myeloid leukemia(AML),no significant improvement of long-term survival rate,recurrent and refractory AML of elderly.Incidence rate of the disease increases with age,the older the patient,the worse prognosis.B-cell lymphoMA 2 gene(Bcl-2)is an important regulator of mitochondrial apoptosis.Venetoclax,as the first approved Bcl-2 inhibitor,has shown high safety in treatment of AML and plays a crucial role in programmed cell death process of tumor cells.However,compared with other drug combination therapy,monotherapy has limited effect with drug resistance,so combination therapy has been a new trend in treatment.During recent years,many studies have found,induction chemotherapy based on Ven is more effective and safer than traditional chemotherapy.The emergence and application of Ven has greatly changed AML treatment pattern,especially for complex and refractory AML,and elderly AML patients not suitable for intensive chemotherapy.The paper mainly reviews research progress of Bcl-2 inhibitor Ven combined with chemotherapy drugs in treatment of AML.

关 键 词：维奈克拉 联合用药 急性髓细胞白血病 

分 类 号：R73[医药卫生—肿瘤]